Where does Nurix Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$264.46M-36.6%	-$193.57M-34.5%	-$143.95M+20.2%	-$180.36M-53.9%
Depreciation and amortization	$8.74M-6.2%	$9.32M+23.7%	$7.53M+39.2%	$5.41M+100%
Stock-based compensation	$37.97M+11.9%	$33.93M+0.8%	$33.67M+19.7%	$28.13M+78.0%
Gain (loss) on sale of assets	——	-$31K+94.4%	-$556K—	——
Change in accounts payable	——	$5.21M+223%	$1.61M—	——
Change in accrued liabilities	$17.31M+46.5%	$11.82M+278%	$3.12M-58.3%	$7.49M+20.4%
Change in other assets	——	$459K—	——	——
Change in deferred revenue	-$36.98M—	——	$19.51M+173%	-$26.63M—
Non-cash operating lease expense	$10.12M+42.3%	$7.11M+16.2%	$6.12M+12.1%	$5.46M+65.8%
Change in operating lease liabilities	-$5.07M+21.1%	-$6.42M-2.4%	-$6.27M-28.7%	-$4.87M+5.3%
Net cash from operating activities	-$249.47M-44.5%	-$172.58M—	——	-$159.81M-89.4%
Capital expenditures	$14M+51.0%	$9.27M+10.4%	$8.4M-31.4%	$12.24M+116%
Proceeds from maturities/sales of investments	$617.54M+34.4%	$459.51M+42.2%	$323.04M+15.9%	$278.81M+16.7%
Net cash from investing activities	$147.85M+157%	-$257.71M—	——	——
Proceeds from issuance of common stock	$0-100%	$289.76M—	$0-100%	$19.4M—
Net cash from financing activities	$238.64M-50.9%	$485.67M+14,997%	$3.22M-97.3%	$117.33M-23.8%
Net increase (decrease) in cash	$137.03M—	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$10.32M-8.6%	$11.29M+108%	$5.42M—	——
Gain/(loss) on dispositions, net	——	-$31K+94.4%	-$556K—	——
Operating lease liabilities	-$5.07M+21.1%	-$6.42M-2.4%	-$6.27M-28.7%	-$4.87M+5.3%
Other current liabilities	$17.31M+46.5%	$11.82M+278%	$3.12M-58.3%	$7.49M+20.4%
Increase (Decrease) in Prepaid Expense and Other Assets	——	$459K—	——	——
Operating lease right-of-use asset amortization	$10.12M+42.3%	$7.11M+16.2%	$6.12M+12.1%	$5.46M+65.8%
Proceeds from disposition of marketable securities and other investments	——	$459.51M+42.2%	$323.04M+15.9%	$278.81M+16.7%
Issuance of stock under employee stock plans	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——
Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities	$0-100%	$117K—	$0—	$0—
Increase Decrease In Contract With Customer Liability	-$36.98M—	——	$19.51M+173%	-$26.63M—
Increase Decrease In Operating Lease Liability	-$5.07M+21.1%	-$6.42M-2.4%	-$6.27M-28.7%	-$4.87M+5.3%
Issuance costs related to equity financing included in accrued expenses and other current liabilities	$371K—	$0—	$0—	——
Leased assets obtained in exchange for operating lease liabilities	$32.49M—	——	——	$5.07M+114%
Free cash flow	-$263.47M-44.9%	-$181.86M—	——	-$172.05M-91.1%
Free cash flow	-$263.47M-44.9%	-$181.86M—	——	-$172.05M-91.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Nurix Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.